Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations
- 18 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Oncology
- Vol. 21 (4), 1-15
- https://doi.org/10.1007/s11864-020-0723-5
Abstract
Opinion statement The MET exon 14 skipping mutation is found in approximately 3% of lung adenocarcinomas and slightly more than 2% of lung squamous cell carcinomas. In recent years, more and more evidence has shown that MET inhibitors have achieved good anti-tumor effect in patients with MET exon 14 skipping mutation, suggesting that MET exon 14 skipping mutation may be a new target for NSCLC patients. Patients with positive MET exon 14 skipping mutation are recommended to be administered MET inhibitors, and crizotinib is recommended by the NCCN guideline. Due to the presence of gene amplification, second site mutation, bypass activation, and pathological type transformation, one of the inevitable problems of targeted therapy is drug resistance. If type I MET inhibitors (crizotinib, capmatinib, tepotinib, savolitinib) drug resistance is developed, type II MET inhibitors (cabozantinib, glesatinib, merestinib) can be considered.Keywords
This publication has 57 references indexed in Scilit:
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Journal of Thoracic Oncology, 2016
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor PrognosisClinical Cancer Research, 2016
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene MutationsJournal of Clinical Oncology, 2016
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionJournal of Clinical Oncology, 2016
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 SkippingCancer Discovery, 2015
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsCancer Discovery, 2015
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- An overview of the c-MET signaling pathwayTherapeutic Advances in Medical Oncology, 2011
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 2009
- Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung CancerCancer Research, 2005